Arbaclofen placarbil: Development discontinued

Xenoport discontinued development of arbaclofen placarbil after top-line data from a 13-week, double-blind, U.S. Phase III trial in 228 patients with spasticity due to MS showed that the product missed the co-primary endpoints of improving physician-rated Maximum Ashworth Scale and 7-point PGIC

Read the full 423 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE